Benign - DEPART trial
2025 has been a landmark year for benign conditions within our radiation oncology research portfolio. The DEPART randomised trial for patients with Dupuytrens’ Disease (DD) is a flagship example of our commitment to innovation and patient-centred care in this area. We are proud to partner internationally with colleagues at the University Medical Center Gronigen in the Netherlands who have contributed significantly to the recruitment and follow-up of patients in DEPART. This international collaboration is a first for a GenesisCare investigator-initiated trial. This year, DEPART achieved significant recognition, with our paper on interim acute toxicity and quality-of-life outcomes accepted by the prestigious Red Journal, and the results presented by Prof Jarad Martin at the ASTRO Annual Meeting in San Francisco. Key findings • Low dose radiation therapy (LDRT) for DD is well-tolerated with minimal ongoing toxicities • Quality-of-life (QOL) is possibly improved by LDRT
Adverse events after adjuvant radiation therapy for Dupuytren’s disease in the DEPART randomized trial - Tanya Burgess, Eric Wegener, Brett McClelland, David Hunter-Smith, Paul M.N. Werker, Jarad Martin, , DEPART Clinical Trial Collaboration, DEPART Clinical Trial Collaboration, 2025 Prof Jarad Martin was also privileged to present the Presidential Symposium at ASTRO in 2025, highlighting the expertise he and GenesisCare offer in this area. This milestone reflects the dedication of our multidisciplinary team, whose efforts are contributing to advancing the understanding of radiation therapy for non-malignant conditions. Our collaborative approach has enabled us to deliver high-quality evidence that informs best practice, ensuring that patients with non-malignant diseases receive care that is both effective and minimally disruptive to their daily lives. Looking ahead, we are excited to extend the reach of the DEPART trial by onboarding highly regarded international colleagues. Prof Jarad Martin has been actively fostering global partnerships, aiming to collaborate with exceptional clinicians and researchers from the USA and Canada to strengthen recruitment to the adjuvant cohort of the study. These international collaborations will enrich our trial with diverse expertise and perspectives, ultimately benefiting patients worldwide. In addition to the DEPART trial, we plan to launch the PROSPECT OA registry study in early 2026, which will focus on prospective data collection using radiation therapy to treat osteoarthritis. This initiative further demonstrates our commitment to expanding research and treatment in non-malignant conditions and leveraging research as a foundation for future growth and collaboration. Together, with our local and international partners, we are shaping the future of radiation oncology for non-malignant diseases, delivering hope, improving outcomes, and setting new standards in care.
• Follow-up ongoing to assess longer term toxicities, QOL and impact on disease control
If you would like to read the full article, you can access it here: Full text: Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren’s disease (Red Journal) redjournal.org. This paper also won the Chris Atkinson Prize for best proffered Radiation Oncology paper at the 2025 RANZCR ASM. Another DEPART publication focusing on toxicity following adjuvant RT was published this year in the Sage and Journal of Hand Surgery (European Volume).
Prof Jarad Martin presenting at ASTRO, 2025
22
23
Made with FlippingBook Annual report maker